Guideline-Based Management of Muscle-Invasive Bladder Cancer: NCCN, ICUD, and EAU

  • Amanda N. Calhoun
  • Kamal S. PoharEmail author


Muscle-invasive bladder cancer is a complex and lethal disease that requires dedicated and often multidisciplinary management. It is imperative that clinicians are well-informed of the most recent practice guidelines in the care of muscle-invasive bladder cancer to ensure optimum delivery of care. Consensus guidelines are useful as they serve as a summary of the best available evidence that allows the clinician to more easily put evidence into practice. Consensus guidelines for muscle-invasive bladder cancer have been generated by authorities in the field and published by the National Comprehensive Cancer Network (NCCN), International Consultation of Urologic Disease (ICUD), and European Association of Urology (EAU). In this chapter, we have reviewed and compared the clinical practice guidelines for the management of muscle-invasive bladder cancer of the NCCN, ICUD, and EAU.


Clinical practice guidelines Muscle-invasive bladder cancer Radical cystectomy Bladder preservation Chemotherapy Radiation therapy Surveillance 


  1. 1.
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Bladder Cancer (Version 1.2013) [cited September 25, 2013]. Available from:
  2. 2.
    Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Khurshid AG, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:45–57.PubMedCrossRefGoogle Scholar
  3. 3.
    Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma—neoadjuvant and adjuvant settings. Eur Urol. 2013;63:58–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Witjies JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer [cited September 25, 2013]. Available from:
  5. 5.
    Stenzl A, Nagele U, Kuczyk M, Sievert KD, Anastasiadis A, Seibold J, et al. Cystectomy—technical considerations in male and female patients. Eur Urol Suppl. 2005;3:138–46.Google Scholar
  6. 6.
    Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 2008;179:873–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Abol-Enein H, Tilki D, Mosbah A, El-Baz M, Shokeir A, Nabeeh A, et al. Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol. 2011;60:572–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Gore JL, Lia J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare Analysis. Cancer. 2009;115(5):988–96.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Alva AS, Tallman CT, He C, Hussain MH, Hafez K, Montie JE, et al. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer. Cancer. 2012;118:44–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:202–6. discussion 205–6.CrossRefGoogle Scholar
  12. 12.
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Donat SM, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113:2471–7.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer. 2009;115:792–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2009). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009. Accessed Jan 2014)
  16. 16.
    Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. Eur J Cancer. 2006;42:50–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Sys Rev 2006:CD006018.Google Scholar
  19. 19.
    Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55:177–86.PubMedCrossRefGoogle Scholar
  20. 20.
    Meeks JJ, Joaquim B, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012;62:523–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the bladder. Clin Cancer Res. 2010;16:4461–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination therapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011;108(5):693–9.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64(2):307–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Holzbeierlein JM, Lopez-Corona E, Bochner BH, Herr HW, Donat SM, Russo P, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol. 2004;172:878–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19:89–93.PubMedGoogle Scholar
  26. 26.
    Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C. Feasibility of transurethral resection for muscle invasive infiltrating carcinoma of the bladder: long term follow up of a prospective study. J Urol. 1998;159:95–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14:2901–7.PubMedGoogle Scholar
  28. 28.
    James JD, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88.PubMedCrossRefGoogle Scholar
  29. 29.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRefGoogle Scholar
  30. 30.
    Ghoneim MA, Abdel-Latif M, El-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008;180(1):121–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE. Upper urinary tract recurrence after radical cystectomy for bladder cancer—who is at risk? J Urol. 2009;182:2632–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of UrologyOhio State University Wexner Medical CenterColumbusUSA
  2. 2.Department of UrologyOhio State University Wexner Medical CenterColumbusUSA

Personalised recommendations